Neoteryx delivers on the promise of blood microsampling innovation. We are focused on delivering simple, quantitative microsampling solutions for biological samples, amenable to high throughput processing. Our customers work to advance pharmaceutical development, personalized medicine, biotechnology research and clinical research.Who is Neoteryx? | Video
Incubated at Phenomenex for four years, the research and development of VAMS® technology occurred with the cooperation of global pharmaceutical companies. VAMS sampling simplifies the collection, storage, and transportation of biological specimens through the instrument known as the Mitra® Microsampling Device, commercially launched by Neoteryx in late 2016. Mitra devices accurately collect microliters of biological fluid in seconds.
A chat over the limitations of Dried Blood Spot (DBS) cards between Dr. James Rudge (Phenomenex) and Dr. Neil Spooner (GlaxoSmithKline) reveals the market potential for a next generation dried matrix microsampling technology.
10 µL devices based on VAMS® technology are thoroughly tested by five leading pharmaceutical organizations, validating that they collected a fixed, precise volume of biological fluid.
As a CE-IVD registered device, Neoteryx is prepared to introduce the in vitro diagnostic European market to next generation dried blood collection and transportation.
Neoteryx expands into the United Kingdom to better serve its growing European customer base.
The Mitra® microsampler is listed as an exempt medical device.
Manufacturing expands into a new building - Neo 2 - to better accommodate the growing need to manufacture more of this technology.
With the release of the 30 µL tips, users of Mitra® devices now collect more sample. This facilitates detection of analytes with low concentrations and multiplex analyses from one sampler tip.
At only five years old, VAMS® technology rides a wave of commercial and academic interest to rack up its 65th publication.